{"filing":{"accession_number":"0001395064-26-000337","cik":"0001395064","ticker":"TKPHF","company_name":"TAKEDA PHARMACEUTICAL CO LTD","form":"6-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"form6k_091426.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1395064/000139506426000337/form6k_091426.htm"},"events":[{"id":33079,"run_id":30405,"accession_number":"0001395064-26-000337","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The exhibit announces FDA acceptance of a New Drug Application (NDA) under Priority Review for Takeda's investigational drug zasocitinib for moderate-to-severe plaque psoriasis, with a PDUFA target action date in Q1 2027. This is a material regulatory milestone in the drug development pipeline—a significant operational and strategic event for a biopharmaceutical company—but does not fit the specific event types for earnings, M\u0026A, executive changes, or financial obligations. The announcement discloses Phase 3 clinical trial results supporting the NDA and represents progress toward potential commercialization of a next-generation therapeutic candidate.","company_name":"TAKEDA PHARMACEUTICAL CO LTD","ticker":"TKPHF","filing_date":"2026-09-14","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":36417,"accession_number":"0001395064-26-000337","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The exhibit announces FDA acceptance of a New Drug Application (NDA) under Priority Review for Takeda's investigational drug zasocitinib for moderate-to-severe plaque psoriasis, with a PDUFA target action date in Q1 2027. This is a material regulatory milestone in the drug development pipeline—a significant operational and strategic event for a biopharmaceutical company—but does not fit the specific event types for earnings, M\u0026A, executive changes, or financial obligations. The announcement discloses Phase 3 clinical trial results supporting the NDA and represents progress toward potential commercialization of a next-generation therapeutic candidate.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T10:26:37.588958+00:00","company_name":"TAKEDA PHARMACEUTICAL CO LTD","ticker":"TKPHF","filing_date":"2026-09-14"}]}